AU2014301220A1 - Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) - Google Patents
Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) Download PDFInfo
- Publication number
- AU2014301220A1 AU2014301220A1 AU2014301220A AU2014301220A AU2014301220A1 AU 2014301220 A1 AU2014301220 A1 AU 2014301220A1 AU 2014301220 A AU2014301220 A AU 2014301220A AU 2014301220 A AU2014301220 A AU 2014301220A AU 2014301220 A1 AU2014301220 A1 AU 2014301220A1
- Authority
- AU
- Australia
- Prior art keywords
- dichlorophenyl
- pyrazol
- yloxy
- substituted
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382246.0A EP2818166A1 (de) | 2013-06-26 | 2013-06-26 | Verwendung von sigma-Rezeptorliganden zur Vorbeugung und Behandlung von Schmerzen im Zusammenhang mit interstitieller Zystitis/Blasenschmerzsyndrom (IC/BPS) |
| EP13382246.0 | 2013-06-26 | ||
| PCT/EP2014/063360 WO2014207024A1 (en) | 2013-06-26 | 2014-06-25 | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2014301220A1 true AU2014301220A1 (en) | 2016-02-18 |
Family
ID=48700506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014301220A Abandoned AU2014301220A1 (en) | 2013-06-26 | 2014-06-25 | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20160151377A1 (de) |
| EP (2) | EP2818166A1 (de) |
| JP (1) | JP2016523276A (de) |
| KR (1) | KR20160023839A (de) |
| CN (1) | CN105377257A (de) |
| AR (1) | AR096709A1 (de) |
| AU (1) | AU2014301220A1 (de) |
| BR (1) | BR112015032343A8 (de) |
| CA (1) | CA2916568A1 (de) |
| HK (1) | HK1221656A1 (de) |
| IL (1) | IL243362A0 (de) |
| MA (1) | MA38711A1 (de) |
| MX (1) | MX2015017761A (de) |
| PH (1) | PH12015502815A1 (de) |
| RU (1) | RU2016102149A (de) |
| SG (1) | SG11201510408XA (de) |
| TN (1) | TN2015000558A1 (de) |
| TW (1) | TWI629984B (de) |
| WO (1) | WO2014207024A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (de) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon |
| EP2353591A1 (de) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon |
| EP2353598A1 (de) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz |
| EP2388005A1 (de) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie |
| EP2415471A1 (de) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie |
| EP2524694A1 (de) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes |
| CA2933057A1 (en) * | 2013-12-17 | 2015-06-25 | Laboratorios Del Dr. Esteve, S.A. | Gabapentinoids and sigma receptor ligands combinations |
| CA2933511A1 (en) | 2013-12-17 | 2015-06-25 | Laboratorios Del Dr. Esteve, S.A. | Serotonin-norepinephrine reuptake inhibitors (snris) and sigma receptor ligands combinations |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| KR20250116520A (ko) | 2024-01-25 | 2025-08-01 | 가톨릭대학교 산학협력단 | 칸나비디올을 유효성분으로 포함하는 방광 통증 증후군의 예방 또는 치료용 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002315814B2 (en) * | 2001-07-10 | 2007-05-31 | Astellas Pharma Inc. | Medicinal composition for treatment of interstitial cystitis |
| WO2006021462A1 (en) | 2004-08-27 | 2006-03-02 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| TWI356699B (en) * | 2004-11-10 | 2012-01-21 | Kissei Pharmaceutical | Agent for treating interstitial cystitis and agent |
| WO2007025613A2 (en) * | 2005-07-15 | 2007-03-08 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
| EP1994032A1 (de) * | 2006-03-01 | 2008-11-26 | Laboratorios del Dr. Esteve S.A. | Pyrazolderivate als inhibitoren des sigma-rezeptors |
| CN101395157A (zh) * | 2006-03-01 | 2009-03-25 | 伊斯特芬博士实验室有限公司 | 作为西格玛受体抑制剂的吡唑衍生物 |
| EP2116539A1 (de) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon |
| EP2113501A1 (de) * | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazole als Sigma rezeptor-Hemmer |
| EP2353591A1 (de) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon |
| EP2353598A1 (de) * | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz |
| EP2460804A1 (de) * | 2010-12-03 | 2012-06-06 | Laboratorios Del Dr. Esteve, S.A. | 5-Methyl-1(Naphtalen-2-yl)-1h-Pyrazolderivate and ihre Verwendung zur Verstärkung der Wirkung von Opioid-Analgetika |
| EP2460519A1 (de) * | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei Knochenkrebsschmerz |
| SMT201700035T1 (it) * | 2011-05-13 | 2017-03-08 | Array Biopharma Inc | Composti di pirrolidinil urea, pirrolidinil tiourea e pirrolidinil guanidina come inibitori di chinasi trka |
| EP2524694A1 (de) * | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes |
-
2013
- 2013-06-26 EP EP13382246.0A patent/EP2818166A1/de not_active Withdrawn
-
2014
- 2014-06-24 AR ARP140102374A patent/AR096709A1/es unknown
- 2014-06-24 TW TW103121723A patent/TWI629984B/zh not_active IP Right Cessation
- 2014-06-25 CN CN201480040098.1A patent/CN105377257A/zh active Pending
- 2014-06-25 RU RU2016102149A patent/RU2016102149A/ru not_active Application Discontinuation
- 2014-06-25 JP JP2016522457A patent/JP2016523276A/ja active Pending
- 2014-06-25 CA CA2916568A patent/CA2916568A1/en not_active Abandoned
- 2014-06-25 KR KR1020167001865A patent/KR20160023839A/ko not_active Withdrawn
- 2014-06-25 SG SG11201510408XA patent/SG11201510408XA/en unknown
- 2014-06-25 BR BR112015032343A patent/BR112015032343A8/pt not_active Application Discontinuation
- 2014-06-25 MA MA38711A patent/MA38711A1/fr unknown
- 2014-06-25 TN TN2015000558A patent/TN2015000558A1/en unknown
- 2014-06-25 AU AU2014301220A patent/AU2014301220A1/en not_active Abandoned
- 2014-06-25 EP EP14734099.6A patent/EP3013338A1/de not_active Withdrawn
- 2014-06-25 WO PCT/EP2014/063360 patent/WO2014207024A1/en not_active Ceased
- 2014-06-25 HK HK16109869.1A patent/HK1221656A1/zh unknown
- 2014-06-25 US US14/900,786 patent/US20160151377A1/en not_active Abandoned
- 2014-06-25 MX MX2015017761A patent/MX2015017761A/es unknown
-
2015
- 2015-12-17 PH PH12015502815A patent/PH12015502815A1/en unknown
- 2015-12-27 IL IL243362A patent/IL243362A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL243362A0 (en) | 2016-02-29 |
| TN2015000558A1 (en) | 2017-04-06 |
| MX2015017761A (es) | 2016-07-06 |
| CA2916568A1 (en) | 2014-12-31 |
| PH12015502815A1 (en) | 2016-03-21 |
| RU2016102149A3 (de) | 2018-05-25 |
| CN105377257A (zh) | 2016-03-02 |
| SG11201510408XA (en) | 2016-01-28 |
| TW201536295A (zh) | 2015-10-01 |
| EP3013338A1 (de) | 2016-05-04 |
| KR20160023839A (ko) | 2016-03-03 |
| EP2818166A1 (de) | 2014-12-31 |
| RU2016102149A (ru) | 2017-08-02 |
| BR112015032343A2 (pt) | 2017-09-26 |
| MA38711A1 (fr) | 2017-12-29 |
| BR112015032343A8 (pt) | 2018-01-23 |
| US20160151377A1 (en) | 2016-06-02 |
| AR096709A1 (es) | 2016-01-27 |
| JP2016523276A (ja) | 2016-08-08 |
| HK1221656A1 (zh) | 2017-06-09 |
| TWI629984B (zh) | 2018-07-21 |
| WO2014207024A1 (en) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2818166A1 (de) | Verwendung von sigma-Rezeptorliganden zur Vorbeugung und Behandlung von Schmerzen im Zusammenhang mit interstitieller Zystitis/Blasenschmerzsyndrom (IC/BPS) | |
| TWI585083B (zh) | 用於預防及/或治療手術後疼痛的σ配子 | |
| KR101855358B1 (ko) | 골암통증에서의 시그마 리간드의 용도 | |
| US9789117B2 (en) | Use of sigma ligands in diabetes type-2 associated pain | |
| US20160220574A1 (en) | Nsaid and sigma receptor ligand combinations | |
| MX2013001328A (es) | Uso de ligandos sigma en la hiperalgesica inducida por opioides. | |
| EP2792352A1 (de) | Alpha-2-Adrenorezeptor und Sigmarezeptor-Ligande enthaltenden Kombinationen | |
| CN105873580A (zh) | 加巴喷丁类化合物与σ受体配体的组合物 | |
| TW201532605A (zh) | α-2腎上腺素受體及σ受體配體組合 | |
| HK1179511B (en) | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |